​

Curanex Pharmaceuticals Stock (NASDAQ:CURX)

OwnershipFinancialsChart

Previous Close

$0.33

52W Range

$0.26 - $9.18

50D Avg

$0.41

200D Avg

$0.98

Market Cap

$9.35M

Avg Vol (3M)

$194.44K

Beta

-3.07

Div Yield

-

CURX Company Profile

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

-

IPO Date

Aug 26, 2025

Website

CURX Performance

CURX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-4.24M$-365.06K$-19.30K
Net Income$-4.23M$-361.51K$-19.20K
EBITDA$-4.24M$-290.39K$-17.48K
Basic EPS$-0.17$-0.01-
Diluted EPS$-0.17$-0.01-

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
LGVNLongeveron Inc.
ASBPAspire Biopharma Holdings, Inc.
DAREDaré Bioscience, Inc.
CUPRCuprina Holdings (Cayman) Limited Class A Ordinary Shares
HOTHHoth Therapeutics, Inc.
CRISCuris, Inc.
BCTXBriaCell Therapeutics Corp.
PULMPulmatrix, Inc.
LPTXLeap Therapeutics, Inc.
PALIPalisade Bio, Inc.